Malcolm et al. 2018: Ibogaine OUD Withdrawal & Craving Scores (n=50) — PubMed Expansion Observational Pick

Definition box

Definition: PubMed expansion pick (2016–2020 OUD observational, not previously drafted as a primary spoke): Malcolm B.J., Polanco M., & Barsuglia J.P. (2018) *Changes in Withdrawal and Craving Scores in Participants Undergoing Opioid Detoxification Utilizing Ibogaine*, *Journal of Psychoactive Drugs* (doi: 10.1080/02791072.2018.1447175; PMID 29608409). Prospective-style observational scoring in n=50 participants with OUD during a week-long clinic detoxification protocol using ibogaine: ASI baseline characterization; COWS, SOWS, and BSCS at 48 h and 24 h pre-dose and 24 h and 48 h post-dose. At 48 hours post-ibogaine, authors report substantially lowered withdrawal/craving versus baseline—78% without objective clinical withdrawal signs, 79% minimal cravings, 68% subjective withdrawal in the mild range. Route = clinic oral ibogaine context (Crossroads/Tijuana setting in author affiliations)—not psychoactive IV ibogaine infusion. Observational, not RCT; not a cure claim; not FDA-approved. Ibogaine is U.S. Schedule I. QTc/cardiac risk remains central (this paper is an outcomes/withdrawal-score report, not a cardiac-safety trial).

Quotable answer (56 words)

Malcolm, Polanco, and Barsuglia’s 2018 Journal of Psychoactive Drugs observational study in 50 people with opioid use disorder found large short-term drops in COWS, SOWS, and craving scores after clinic ibogaine detoxification. Observational withdrawal scores are not controlled proof and not psychoactive IV ibogaine infusion evidence. Schedule I; screen for QTc risk.

Why this paper was chosen (PubMed expansion rule)

Already covered strong OUD observationals: Brown & Alper 2018, Noller 2018, Mash 2018, Glue noribogaine 2016, Knuijver 2021. Malcolm 2018 adds a distinct, frequently cited n=50 COWS/SOWS/BSCS short-window detoxification dataset from a Mexico clinic protocol—ideal next spoke. Soft CTA: /safety-and-screening → /apply.

Alternates considered (not chosen as this spoke’s primary): Davis et al. 2017 *J Psychedelic Stud* subjective effectiveness survey (n=88)—strong but more retrospective survey than timed withdrawal scales; reserved for future inventory if needed.

What was studied

| Feature | Accurate description | |---------|----------------------| | Citation | Malcolm B.J., Polanco M., Barsuglia J.P. *J Psychoactive Drugs*. 2018. doi 10.1080/02791072.2018.1447175. PMID 29608409 | | Type | Observational detoxification scoring study (authors note further controlled trials needed) | | N | 50 participants with OUD | | Setting | Week-long clinic detoxification protocol (author affiliations: Crossroads Treatment Center, Tijuana, Mexico; WesternU pharmacy) | | Route | Oral ibogaine in clinic protocol context—not psychoactive IV brand study | | Measures | ASI (baseline); COWS; SOWS; BSCS at −48 h, −24 h, +24 h, +48 h relative to ibogaine | | Headline 48 h results | 78% no objective withdrawal signs; 79% minimal opioid cravings; 68% mild-range subjective withdrawal | | What it is not | RCT; 12-month durability primary; FDA approval; IV ibogaine proof; cardiac QT study; cure claim |

Methods (plain language)

Clinicians tracked standard opioid withdrawal and craving questionnaires before and after ibogaine during a structured detox week. When scores fall, that is meaningful acute pharmacology/clinic-process signal. Without randomization, expectancy, adjunct meds, and selection still confound “ibogaine alone did X.”

Key findings (no hype)

• Withdrawal and craving scores were significantly lower at 48 hours post-ibogaine versus baseline comparisons reported by the authors.
• Majority of participants no longer showed objective COWS-range clinical withdrawal signs at that snapshot.
• Craving ratings clustered toward minimal for most respondents at 48 hours.
• Authors explicitly say results warrant rigorous controlled trials—editorial pages should repeat that sentence, not delete it.
• Short observation window does not answer 6–12 month abstinence probability (see Brown/Noller/Davis durability-adjacent papers for longer views with their own biases).

Honest reading: Strong acute observational detox signal; weak causal certainty; zero license for “100% detox miracle” ads.

How it sits beside other OUD observationals

| Paper | Distinct contribution | |-------|----------------------| | Brown & Alper 2018 | n=30; SOWS + ASI composites to 12 months (/blog/brown-alper-2018-ibogaine-oud) | | Noller 2018 | NZ legal setting; 12-month ASI + BDI; one death (/blog/noller-2018-ibogaine-new-zealand) | | Mash 2018 | Large open-label N=191 craving/mood (/blog/mash-2018-ibogaine-detox-frontiers) | | Malcolm 2018 | n=50 timed COWS/SOWS/BSCS peri-dose clinic scores | | Knuijver 2021 | Safety-first QT/ataxia in n=14 (/blog/knuijver-2021-ibogaine-qtc-safety) |

Cardiac / YMYL gap in this paper

Malcolm 2018 is optimized for withdrawal psychometrics, not continuous QTc tables. Readers must still visit cardiac spokes before any logistics (/blog/ibogaine-mortality-cardiac-risk, /blog/corkery-ibogaine-fatalities, /safety-and-screening). Mexico clinic observation ≠ U.S. FDA clinic.

Route honesty & entity clarity

Clinic oral detox protocols ≠ physician-supervised psychoactive IV ibogaine infusion. Do not paste Malcolm’s 78%/79% figures into IV brand ads as route-proof (/blog/ibogaine-oral-vs-iv; /what-is-ibogaine-infusion).

Limits and confounders

| Limit | Why it matters | |-------|----------------| | No randomized control | Time, setting, adjuncts confound | | Single clinic network | Generalizability limits | | Short ±48 h window | Not durable recovery proof | | Self-report craving | Subject to expectancy | | Cardiac not primary | Incomplete risk picture if read alone |

What this does NOT prove for IV ibogaine infusion brand

| Claim | Status | |-------|--------| | “78% cured forever” | False | | “Proves psychoactive IV ibogaine” | False | | Useful acute oral observational detox signal? | Yes—with labels |

SEO use of the 78% / 79% / 68% figures

Allowed pattern: “In Malcolm et al. 2018’s observational n=50 clinic sample, authors reported that at 48 hours post-ibogaine, 78% lacked objective clinical withdrawal signs on COWS-framed assessment, 79% reported minimal cravings, and 68% had mild-range subjective withdrawal—findings that still require controlled replication and do not establish psychoactive IV ibogaine efficacy.”

Forbidden pattern: “Ibogaine has a 78% cure rate.” Percentages without method class, time window, and observational label are YMYL malpractice.

Aftercare reminder

Even dramatic 48-hour score drops do not replace relapse-prevention planning, housing, and psychiatric follow-up (/blog/ibogaine-aftercare-integration). Brown/Noller longer follow-ups show trajectories can change after the acute window—another reason not to weaponize Malcolm’s snapshot as lifelong prognosis.

Soft CTA

Withdrawal-score hope is not a screening plan. Start here: /safety-and-screening → /apply for supervised IV ibogaine infusion questions.

FAQ

Which paper did this PubMed expansion choose? Malcolm, Polanco & Barsuglia 2018, *J Psychoactive Drugs*, doi **10.1080/02791072.2018.1447175**, PMID **29608409**.

Why this one? Strong n=50 COWS/SOWS/BSCS OUD detox observational not already given a primary spoke; distinct from Brown/Noller/Mash.

Is it an RCT? No. Authors call for controlled trials.

What happened at 48 hours? Authors report large proportions with minimal objective withdrawal and craving on standard scales—observational snapshot only.

Was the route IV ibogaine? No—clinic oral ibogaine context; not psychoactive IV brand proof.

Does this erase cardiac risk? No. Pair with QT/fatality spokes.

Is ibogaine FDA-approved? No. Schedule I.

Where should screening start? /safety-and-screening, then /apply if appropriate.

Sources (selected)

1. Malcolm B.J., Polanco M., Barsuglia J.P. *J Psychoactive Drugs*. 2018. doi: 10.1080/02791072.2018.1447175. PMID: 29608409.
2. Brown T.K., Alper K. *Am J Drug Alcohol Abuse*. 2018. doi: 10.1080/00952990.2017.1320802.
3. Noller G.E. et al. *Am J Drug Alcohol Abuse*. 2018. doi: 10.1080/00952990.2017.1310218.
4. Mash D.C. et al. *Front Pharmacol*. 2018. doi: 10.3389/fphar.2018.00529.
5. Knuijver T. et al. *Addiction*. 2021. doi: 10.1111/add.15448.
6. 21 CFR 1308.11 — ibogaine Schedule I (United States).

Medical disclaimer

Educational research synopsis only—not medical, psychiatric, or legal advice, and not a guarantee of outcomes. Ibogaine can prolong the QTc interval and has been associated with serious cardiac events including torsades de pointes and death in some contexts. Ibogaine is Schedule I in the United States and is not FDA-approved for any indication. Provisional Mexico programs discussed on this site are not U.S. FDA clinics. Soft CTAs: /safety-and-screening, /apply.

Malcolm 2018 is an observational clinic oral detox scoring study—not a cure claim and not psychoactive IV ibogaine efficacy proof.